Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Ophthalmology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1507576
This article is part of the Research Topic New Concepts, Advances, and Future Trends in Clinical Research on Eye Diseases View all 7 articles

PLEK2: A Potential Biomarker for Metastasis and Prognostic Evaluation in Uveal Melanoma

Provisionally accepted
Yichong Liu Yichong Liu 1Haiyue Wang Haiyue Wang 2Qian Zhang Qian Zhang 1Xiaodi Gao Xiaodi Gao 1Yiqing Ji Yiqing Ji 1Yuanzhang Zhu Yuanzhang Zhu 1Jingjing Zhang Jingjing Zhang 1Wenjuan Luo Wenjuan Luo 1*
  • 1 Department of Ophthalmology, Affiliated Hospital of Qingdao University, Qingdao, China
  • 2 Binzhou Medical University, Binzhou, Shandong Province, China

The final, formatted version of the article will be published soon.

    Background: Uveal melanoma (UVM) is an aggressive tumor known for its high metastatic rate, making it necessary to delineate potential molecules that may promote the development of UVM. PLEK2 has been found to promote the progression and metastasis of some tumors, but its role in UVM has not yet been reported. Through this study, we hope to explore the effect of PLEK2 on the prognosis of UVM patients and to discover the potential functional role and intrinsic mechanism of PLEK2. Methods: The GEO datasets GSE211763 and GSE149920 were analyzed using GEO2R to identify differentially expressed genes that may be associated with UVM progression and metastasis. A Protein-Protein Interaction Network (PPI) was constructed to identify key molecules. The correlation between PLEK2 expression and overall survival was evaluated via GEPIA2, and clinical characteristics of UVM patients were compared based on PLEK2 levels. PLEK2 expression in UVM cell lines was assessed using the CCLE database and confirmed by qPCR and western blot. A weighted correlation network analysis (WGCNA) was performed, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Finally, a search for miRNAs potentially regulating PLEK2 expression was performed using TargetScan, miRWalk, and TarBase databases. Results: Comparative analysis of the GEO datasets unveiled 79 commonly up-regulated genes and 238 commonly down-regulated genes. The PPI network identified 9 hub genes, with PLEK2 significantly linked to reduced overall survival. Clinical comparisons indicated significant differences in cancer status (p = 0.013) and tumor diameter (p = 0.039) between high and low PLEK2 expression groups. Elevated PLEK2 mRNA levels were confirmed in UVM cell lines compared to retinal pigment epithelial cells. PLEK2 was enriched in the calcium signaling pathway and associated with the WNT/Ca2+ signaling pathway. A total of 21 miRNAs potentially regulating PLEK2 were predicted. Conclusion: PLEK2 is upregulated in UVM and correlates with poor patient prognosis, likely influencing the calcium signaling pathway. PLEK2 represents a promising prognostic biomarker and therapeutic target for UVM.

    Keywords: Uveal Melanoma, PLEK2, Bioinformatics analysis, biomarker, Differentially expressed genes

    Received: 08 Oct 2024; Accepted: 13 Nov 2024.

    Copyright: © 2024 Liu, Wang, Zhang, Gao, Ji, Zhu, Zhang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Wenjuan Luo, Department of Ophthalmology, Affiliated Hospital of Qingdao University, Qingdao, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.